CAS 130641-38-2|Bindarit

Introduction：Basic information about CAS 130641-38-2|Bindarit, including its chemical name, molecular formula, synonyms, physicochemical properties, and safety information, etc.

Table of Contents

1. Names
2. Bindarit BiologicalActivity
3. Chemical & Physical Properties
4. Safety Information
5. Customs
6. Synonyms

Common Name	Bindarit
CAS Number	130641-38-2	Molecular Weight	324.374
Density	1.2±0.1 g/cm3	Boiling Point	542.9±40.0 °C at 760 mmHg
Molecular Formula	C₁₉H₂₀N₂O₃	Melting Point	/
MSDS	/	Flash Point	282.1±27.3 °C

Names

Name	2-[(1-benzylindazol-3-yl)methoxy]-2-methylpropanoic acid
Synonym	More Synonyms

Bindarit BiologicalActivity

Description	Bindarit(AF-2838), a CCL2, CCL7 and CCL8 inhibitor, is an anti-inflammatory agent.Target: OthersBindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8. Oral administration of Bindarit at 50 mg/kg in NZB/W mice delays the onset of proteinuria, significantly protects from renal function impairment, and prolongs survival of NZB/W mice or lupus mice. Bindarit treatment completely MCP-1 up-regulation during the progression of nephritis [1]. Inhibition of MCP-1 with Bindarit also reduces tumor growth and macrophage recruitment, rendering necrotic tumor masses in human melanoma xenografts [2]. Bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointimal macrophage content [3]. Administration of Bindarit results in impaired metastatic disease in prostate cancer PC-3M-Luc2 xenograft mice and impairment of local tumorigenesis in Balb/c mice with murine breast cancer 4T1-Luc cells. In addition, Bindarit treatment significantly decreases the infiltration of tumor-associated macrophages and myeloid-derived suppressor cells in 4T1-Luc primary tumors [4].
Related Catalog	Signaling Pathways >>Others >>OthersResearch Areas >>Inflammation/Immunology
References	[1]. Zoja, C., et al., Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int, 1998. 53(3): p. 726-34. [2]. Gazzaniga, S., et al., Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol, 2007. 127(8): p. 2031-41. [3]. Grassia, G., et al., The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovasc Res, 2009. 84(3): p. 485-93. [4]. Zollo, M., et al., Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis, 2012. 29(6): p. 585-601.

Description

Bindarit(AF-2838), a CCL2, CCL7 and CCL8 inhibitor, is an anti-inflammatory agent.Target: OthersBindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8. Oral administration of Bindarit at 50 mg/kg in NZB/W mice delays the onset of proteinuria, significantly protects from renal function impairment, and prolongs survival of NZB/W mice or lupus mice. Bindarit treatment completely MCP-1 up-regulation during the progression of nephritis [1]. Inhibition of MCP-1 with Bindarit also reduces tumor growth and macrophage recruitment, rendering necrotic tumor masses in human melanoma xenografts [2]. Bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointimal macrophage content [3]. Administration of Bindarit results in impaired metastatic disease in prostate cancer PC-3M-Luc2 xenograft mice and impairment of local tumorigenesis in Balb/c mice with murine breast cancer 4T1-Luc cells. In addition, Bindarit treatment significantly decreases the infiltration of tumor-associated macrophages and myeloid-derived suppressor cells in 4T1-Luc primary tumors [4].

Related Catalog

Signaling Pathways >>Others >>OthersResearch Areas >>Inflammation/Immunology

References

[1]. Zoja, C., et al., Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney Int, 1998. 53(3): p. 726-34.

[2]. Gazzaniga, S., et al., Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. J Invest Dermatol, 2007. 127(8): p. 2031-41.

[3]. Grassia, G., et al., The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovasc Res, 2009. 84(3): p. 485-93.

[4]. Zollo, M., et al., Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin Exp Metastasis, 2012. 29(6): p. 585-601.

Chemical & Physical Properties

Density	1.2±0.1 g/cm3
Boiling Point	542.9±40.0 °C at 760 mmHg
Molecular Formula	C₁₉H₂₀N₂O₃
Molecular Weight	324.374
Flash Point	282.1±27.3 °C
Exact Mass	324.147400
PSA	64.35000
LogP	3.44
Vapour Pressure	0.0±1.5 mmHg at 25°C
Index of Refraction	1.595
InChIKey	MTHORRSSURHQPZ-UHFFFAOYSA-N
SMILES	CC(C)(OCc1nn(Cc2ccccc2)c2ccccc12)C(=O)O

Safety Information

Hazard Codes	Xi
HS Code	2933990090

Customs

HS Code	2933990090
Summary	2933990090. heterocyclic compounds with nitrogen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Synonyms

2-[(1-Benzyl-1H-indazol-3-yl)methoxy]-2-methylpropanoic acid

Bindarit (USAN/INN)

2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid

Propanoic acid, 2-methyl-2-[[1-(phenylmethyl)-1H-indazol-3-yl]methoxy]-

bindarit

Recommended......